pain. Pain, unspecified
Conditions
Interventions
Intervention 1: Intervention group A : Bupivacaine (chemical formula C18H28N2O) from 4 ml vials containing 5 mg/ml,(manufactured by Myungmoon Pharmaceutical Company) 2.5 cc (equivalent to 12.5 mg) + D
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Candidate for elective cesarean section Spinal anesthesia as the method of choice for cesarean section Written consent from the patient to participate in the study No history of allergy to the medications used in the study Lack of blood, infectious, or neurological disorders that may cause problems with spinal anesthesia
Exclusion criteria
Exclusion criteria: Need for changing the anesthesia method during surgery Allergic reaction/hypersensitivity to the medications used in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain Intensity. Timepoint: at 2,4,6,12, and 24 hours after operation. Method of measurement: The patient is asked to rate her pain based on the VAS scale (0 to 10). | — |
Secondary
| Measure | Time frame |
|---|---|
| Analgesic Consumption. Timepoint: As per complain from pain or at defined time points. Method of measurement: The cumulative analgesic consumption during the 24 h after surgery will be recorded.;Possible adverse effects of the intervention. Timepoint: During the 24 h after surgery. Method of measurement: Adverse effects including the hypotension, bradycardia, gastrointestinal symptoms, allergic reactions, and injection site reaction will be recorded. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Alipour
Mashhad University of Medical Sciences
Outcome results
None listed